Latest Information Update: 12 Oct 1999
At a glance
- Originator BTG
- Class Antipsoriatics
- Mechanism of Action 5-lipoxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 12 Oct 1999 No-Development-Reported for Psoriasis in USA (Topical)